Baker McKenzie advised GT Biopharma, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products, on a USD 23.6 million underwritten public offering of units consisting of common stock and warrants. The offering allowed GT Biopharma to uplist to Nasdaq. For more information, please see the company press release.

The Baker McKenzie team included Roger W. Bivans, Tanner Bodine, Sarah Rosales, Harrison Morris and Aaron Goodman, as well as Perrie Weiner and Veleka Peeples-Dyer (FDA regulatory counsel).

About Baker McKenzie
Baker McKenzie is a transactional powerhouse with over 2,500 deal lawyers and expertise in over 46 countries. Our strong global reputation for both issuer and underwriter counsel is based on our ability to successfully navigate the highly complex mix of legal system and cultures in complex cross-border and domestic equity and debt offerings
Explore Our Newsroom